UNSPSC 51334101: Isosulpride

This classification denotes a serotonin antagonist and dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BRT31Y0N0K. European Medicines Agency schedules Isosulpride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08338MIG. Isosulpride generally arises in the molecular formula C15H23N3O4S.

UNSPSC 51334101 Isosulpride is a Commodity code that nominally covers a single pharmaceutical active ingredient, but the recent state and local opportunities tagged to it reflect a broader pattern of public-sector procurement for pharmaceuticals, naloxone and drug-deactivation systems, and pharmacy-benefit program management. State and local issuing bodies treating this code are purchasing finished pharmaceutical products, emergency-response medications, and pharmacy services through county health departments, state HHS commissions, and multistate cooperative purchasing alliances. The work spans procurement of naloxone and drug-safety equipment for community health initiatives, direct-to-manufacturer prescription programs, and generic pharmaceutical supply through authorized wholesale channels. Issuing bodies include county-level health departments (Seminole County, Florida), state HHS agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of Minnesota Department of Administration and participating jurisdictions including Oregon).

Recent activity centers in Florida, Texas, and the Upper Midwest. A representative recent opportunity is Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023), seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and fixed-fee pricing. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription programs and vendor capability for self-insured pharmacy benefit models, signaling potential movement toward alternative pharmacy procurement structures at the state level. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP (S1070000015802, posted January 20, 2026, proposals due March 26, 2026) to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon through three authorized wholesalers, with pricing weighted at 75 percent of evaluation and contract terms of two years with optional extensions.